Alumis (ALMS) vs CryoPort (CYRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CryoPort (CYRX) has outperformed Alumis (ALMS) over the past year, gaining 77.0% versus a gain of 50.1%. Alumis is the larger company by market cap ($902.2 million vs $856.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | CYRX |
|---|---|---|
| Share price | $6.97 | $16.90 |
| Market cap | $902.16M | $855.97M |
| 1-day change | +2.95% | -2.59% |
| YTD return | -30.64% | +80.73% |
| 1-year return | +50.11% | +77.04% |
| 5-year return | — | -75.31% |
| EPS (TTM) | $-3.86 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.35 | $18.36 |
| 52-week low | $4.28 | $7.61 |
| Distance from 52-week high | -77.77% | -7.95% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +360.98% | +16.39% |
| Average volume | 2.43M | 632.63K |
| Shares outstanding | 129.44M | 50.65M |
| Employees | 237 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYRX has outperformed ALMS by 26.9 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
ALMS vs CYRX FAQ
Which is bigger, Alumis or CryoPort?
Alumis (ALMS) is larger, with a market capitalization of $902.16M compared with $855.97M for CryoPort (CYRX).
Which stock has performed better over the past year, ALMS or CYRX?
CYRX returned +77.04% over the past 12 months, compared with +50.11% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and CryoPort in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.